摘要
目的:探讨印记基因SLC22A18(solute carrier family 22,member 18)对人胶质瘤U251细胞化疗药物敏感性的影响及耐药机制的研究。方法:采用脂质体转染法将携带有SLC22A18基因的重组质粒pIRES2-EGFP-SLC22A18转入U251细胞;分别采用RT-PCR和蛋白质印迹法检测SLC22A18 mRNA及蛋白在转染后U251细胞中的表达情况;CCK-8法检测细胞对化疗药物敏感性的变化;FCM法检测SLC22A18表达对细胞凋亡以及对多柔比星在细胞内蓄积浓度的影响。结果:转染SLC22A18基因的U251细胞中有SLC22A18 mRNA及其蛋白的表达;SLC22A18基因转染组U251细胞与对照组细胞比较,U251细胞对紫杉醇的敏感性下降,半数抑制浓度(halfinhibitory concentration,IC50)值上升(t=3.23,P<0.05),对替莫唑胺的敏感性上升,IC50值下降(t=4.28,P<0.05)。SLC22A18基因转染组和空质粒转染组细胞凋亡率分别为(41.35±4.98)%和(6.25±0.82)%,差异有统计学意义(t=12.05,P<0.01)。SLC22A18表达使细胞内多柔比星蓄积浓度明显下降(t=4.25,P<0.05)。结论:SLC22A18表达使人胶质瘤U251细胞对紫杉醇的敏感性下降,对替莫唑胺的敏感性提高,并可能通过降低细胞内化疗药物蓄积产生耐药性。
Objective:To investigate the effect of imprinted SLC22A18 gene on chemotherapeutic sensitivity of U251 human glioma cells,and to explore the possible mechanism of drug-resistance.Methods:The eukaryotic expression plasmid pIRES2-EGFP-SLC22A18 was constructed and transfected into the U251 cells by liposome transfection reagent.The expression levels of SLC22A18 mRNA and protein in U251 cells were detected by RT-PCR and Western blotting,respectively.The change of sensitivity to chemotherapeutic agent for U251 cells was detected by cell counting kit-8(CCK-8) assay.The apoptosis rate and the adriamycin accumulation in the U251 cells induced by SLC22A18 expression were detected by flow cytometry(FCM).Results:The expressions of SLC22A18 mRNA and protein were detected in the U251 cells transfected with SLC22A18 gene.As compared with the empty vector-transfected cells,the sensitivity to paclitaxel was decreased with an increased half inhibitory concentrations(IC50) value while the sensitivity to temozolomide was increased with a decreased IC50 value of the U251 cells transfected with SLC22A18 gene(t = 3.23,P0.05;t = 4.28,P0.05).The apoptosis rates of U251 cells transfeced with SLC22A18 gene and the empty vector were(41.35 ± 4.98) % and(6.25 ± 0.82) %,respectively(t = 12.05,P0.01).The accumulation of adriamycin in the U251 cells with SLC22A18 expression was significantly decreased(t = 4.25,P0.05).Conclusion:The expression of SLC22A18 can reduce the sensitivity to paclitaxel and increase the sensitivity to temozolomide in U251 cells,and the drug-resistance can be induced by decreasing the accumulation of chemotherapeutic agents in U251 cells.
出处
《肿瘤》
CAS
CSCD
北大核心
2012年第2期105-108,141,共5页
Tumor
基金
国家自然科学基金资助项目(编号:30901535)
上海交通大学医学院"新百人计划"资助项目(编号:10XBR01)
上海交通大学医学院附属新华医院集团科研资助项目(编号:10XHJT01)